Pharmacogenomic testing can tell how a drug is likely to work in a certain person. But is it ready for rolling out to the ...
Pharmacogenetic testing, which is used to classify how patients with major depressive disorder (MDD) metabolize medications, reduces adverse drug-gene interactions, new research shows. In a randomized ...
Prostate cancer (PC) is a significant health concern, being the second leading cause of death among American men. The standard treatment for advanced PC often involves androgen deprivation therapy ...
Pharmacogenomic testing uses a patient’s genome to identify their response to a drug, forming a key part of personalized medicine. Hundreds of clinical pharmacogenomics (PGx) tests are currently ...
Steps in the Development & Utilization of Genomic Biomarkers for ADRs Necessary steps in the pathway for development and utilization of pharmacogenomic biomarkers for ADRs begin with observation of ...
At present, pharmacogenomic tests are not available for all medications and are not widely employed as preventive measures in patient care. Globally, health insurance often does not even cover ...
Interviews with scientists and community leaders revealed that returning results fosters trust, respect, and hope among ...
SAN MATEO, Calif., May 28, 2025 /PRNewswire/ -- Helix, a leader in precision health, is announcing the release of a new suite of pharmacogenomics (PGx) tests, including a test designed to identify ...
A new study from Queen Mary University of London found that 9% of all reported adverse drug reactions (ADRs) reported to the UK medicines regulator are associated with medications where side effect ...
Prostate cancer (PC) stands as the second leading cause of death among American men, with about 1 in 8 men diagnosed during their lifetime. PC is categorized into four main types based on disease ...